Jorge Conde invests in therapeutics, diagnostics, life-sciences tools, and healthcare software as a general partner at Andreessen Horowitz. He co-founded genome interpretation company Knome and later led strategy at Syros Pharmaceuticals.
Jorge Conde invests in therapeutics, diagnostics, life-sciences tools, and healthcare software as a general partner at Andreessen Horowitz. He co-founded genome interpretation company Knome and later led strategy at Syros Pharmaceuticals.
Career
Jorge Conde attended Harvard University, earning a MBA, Harvard Business School as well as Harvard-MIT Division of Health Sciences and Technology, earning a MS and also Johns Hopkins University, earning a BA, Biology.
General Partner, Bio + Health at Andreessen Horowitz (a16z) from 2017-06 to Present.Invests in biotechnology and healthcare. Board roles include Asimov, Cartography, Dyno, Earli, Komodo Health, and Octant Bio.
Chief Strategy Officer at Syros Pharmaceuticals from 2016-04 to 2017-03.Led strategy for a biotechnology company developing medicines through gene regulation.
Co-founder and Chief Financial Officer at Knome until 2014.Co-founded the genome interpretation company in 2007 and served in operating roles through 2014; his final executive role was CFO.MMarketing and Operations Manager at MedImmune from 2006 to 2007.Worked in strategic marketing and operations.
FVLife Sciences Summer Associate at Flagship Ventures from 2005 to 2005.
Biotechnology Investment Banker at Morgan Stanley from 2000 to 2003.Advised biotechnology and genomics companies.